We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagCA

888-969-2592

RY 174.21 0.4845% TD 77.21 -0.3099% SHOP 113.1 0.5155% CNR 157.51 -1.1299% ENB 57.59 0.1565% CP 112.08 -0.5678% BMO 129.49 0.3332% TRI 232.87 0.7921% CNQ 49.045 1.1654% BN 76.23 1.3023% ATD 73.74 -0.6066% CSU 4426.6099 0.3812% BNS 73.69 -0.1896% CM 86.29 0.4657% SU 53.56 0.7714% TRP 65.64 0.845% NGT 78.23 1.1246% WCN 250.66 0.2239% MFC 42.08 -0.1898% BCE 46.14 0.2172%

Kane Biotech Inc

Healthcare CA KNE

0.135CAD
0.005(3.85%)

Last update at 2024-10-17T13:39:00Z

Day Range

0.130.14
LowHigh

52 Week Range

0.050.15
LowHigh

Fundamentals

  • Previous Close 0.13
  • Market Cap11.21M
  • Volume38500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.23353M
  • Revenue TTM2.74M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 1.41M
  • Diluted EPS TTM-0.03

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -3.82400M -4.84991M -3.84598M -0.96018M -3.26100M
Minority interest -0.06589M 0.25M 2.56M 2.56M 2.56M
Net income -3.88989M -4.60457M -3.71669M -0.96018M -3.26100M
Selling general administrative 3.72M 4.07M 3.43M 2.66M 2.37M
Selling and marketing expenses - - - - -
Gross profit 1.41M 0.57M 0.53M 0.61M 0.12M
Reconciled depreciation 0.26M 0.19M 0.08M 0.05M 0.07M
Ebit -3.36381M -4.81738M -4.18476M -3.37683M -2.95682M
Ebitda -2.73842M -4.24589M -3.64631M -0.76408M -3.09944M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -3.36381M -4.88356M -4.22437M -3.59020M -3.17883M
Other operating expenses - - - - -
Interest expense 0.82M 0.42M 0.12M 0.14M 0.09M
Tax provision - - - - -
Interest income 0.10M 0.12M 0.04M 0.00045M 0.00962M
Net interest income -0.72186M -0.29413M -0.08326M -0.14122M -0.08016M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.00000M
Total revenue 2.67M 1.61M 1.34M 1.69M 0.51M
Total operating expenses 6.03M 6.49M 5.57M 5.28M 3.69M
Cost of revenue 1.26M 1.04M 0.81M 1.08M 0.39M
Total other income expense net 0.26M 0.33M 0.46M 2.77M -0.00201M
Discontinued operations - - - - -
Net income from continuing ops -3.82400M -4.84991M -3.84598M -0.96018M -3.26100M
Net income applicable to common shares -3.88989M -4.60457M -3.71669M -0.96018M -3.26100M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 5.62M 6.13M 5.04M 2.76M 1.56M
Intangible assets 0.83M 0.83M 0.78M 0.77M 0.95M
Earning assets - - - - -
Other current assets 0.17M 0.14M 0.14M 0.06M 0.04M
Total liab 9.76M 7.70M 3.96M 1.92M 2.54M
Total stockholder equity -6.52257M -3.88598M -1.48958M 0.84M -0.98484M
Deferred long term liab - - - - -
Other current liab 0.21M 1.58M 0.68M 0.78M 0.54M
Common stock 23.13M 22.16M 20.86M 20.16M 17.68M
Capital stock 23.13M 22.16M 20.86M 20.16M 17.68M
Retained earnings -37.10017M -33.21028M -28.60572M -24.88903M -23.92885M
Other liab 0.84M 0.78M 0.35M 0.41M 0.48M
Good will - - - - -
Other assets 0.44M 0.99M 1.36M 0.07M -
Cash 1.10M 1.15M 1.01M 0.83M 0.08M
Cash and equivalents - - - - -
Total current liabilities 6.34M 4.72M 2.92M 1.34M 2.06M
Current deferred revenue - - - - -
Net debt 4.66M 2.34M 1.16M - 0.42M
Short term debt - - - - 0.50M
Short long term debt 4.17M 2.38M 1.51M - 0.50M
Short long term debt total - - - - -
Other stockholder equity - 1.66M 1.84M 1.61M 1.39M
Property plant equipment 1.25M 1.44M 0.16M 0.08M 0.05M
Total current assets 3.10M 2.88M 2.74M 1.84M 0.56M
Long term investments - - - - -
Net tangible assets -7.34903M -4.71463M -2.26650M 0.07M -1.93020M
Short term investments - - - - -
Net receivables 1.06M 1.07M 1.12M 0.36M 0.12M
Long term debt 1.60M 1.12M 0.66M 0.15M -
Inventory 0.76M 0.52M 0.47M 0.59M 0.32M
Accounts payable 1.85M 0.63M 0.66M 0.51M 0.42M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.85M 1.00M
Deferred long term asset charges - - - - -
Non current assets total 2.52M 3.25M 2.30M 0.85M 1.00M
Capital lease obligations 1.09M 1.22M 0.08M 0.02M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.10755M -0.37355M -0.16611M -0.09738M -0.14630M
Change to liabilities -0.08565M 1.29M -0.01811M 0.27M 0.17M
Total cashflows from investing activities -0.10755M -0.37355M -0.16611M -0.16738M -0.14630M
Net borrowings 2.25M 1.25M 2.35M 0.04M 1.10M
Total cash from financing activities 3.10M 2.81M 4.28M 1.81M 1.06M
Change to operating activities -0.03380M 0.00626M -0.08674M -0.01637M -0.01943M
Net income -3.88989M -4.60457M -3.71669M -0.96018M -3.26100M
Change in cash -0.04819M 0.15M 0.17M 0.76M -1.90030M
Begin period cash flow 1.15M 1.01M 0.83M 0.08M 1.98M
End period cash flow 1.10M 1.15M 1.01M 0.83M 0.08M
Total cash from operating activities -3.04347M -2.28919M -3.93897M -0.88537M -2.81445M
Issuance of capital stock 0.97M - 0.70M 1.60M 0.00000M
Depreciation 0.26M 0.19M 0.08M 0.05M 0.07M
Other cashflows from investing activities -0.02000M -0.02000M -0.04000M -0.07000M -0.07000M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory -0.24424M -0.04729M 0.12M -0.26258M -0.19677M
Change to account receivables 0.16M 0.04M -0.27849M -0.24520M 0.00209M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.12059M 0.45M 1.23M 0.18M -0.03955M
Change to netincome 0.78M 0.83M -0.03215M 0.28M 0.42M
Capital expenditures 0.01M 0.19M 0.03M 0.02M 0.00809M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.37838M 1.29M -0.26824M -0.32770M -0.04721M
Stock based compensation 0.28M 1.09M 0.46M 0.03M -
Other non cash items 0.43M -0.07812M -0.40743M 0.03M 0.05M
Free cash flow -3.13102M -2.64274M -4.06508M -1.05275M -3.00030M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KNE
Kane Biotech Inc		 0.005 3.85% 0.14 - - 4.08 107.98 6.84 -6.2504
NGEN
NervGen Pharma Corp		 - -% 2.45 - - - 29.48 -6.9477
ARCH
Arch Biopartners Inc		 0.03 1.60% 1.91 - - 37.82 - 53.05 -28.1027
MIR
MedMira Inc		 - -% 0.08 - - 170.46 - 189.94 -48.7372
TTI
Thiogenesis Therapeutics Corp.		 0.04 6.67% 0.64 - - - 11.86 -163.0787

Reports Covered

Stock Research & News

View All

Profile

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Kane Biotech Inc

290-100 Innovation Drive, Winnipeg, MB, Canada, R3T 6G2

Key Executives

Name Title Year Born
Mr. Marc Edwards Pres, CEO & Director NA
Mr. Ray Dupuis Chief Financial Officer NA
Mr. Kevin Cole Pres & CEO of STEM Animal Health Inc NA
Dr. Gregory S. Schultz Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board 1950
Lorne Gorber Investor Relations NA
Ms. Lori Christofalos VP of Quality & Compliance NA
Ms. Wendy Nachtigall Director of Marketing NA
Nicole Sendey Investor Relations Adviser NA
Mr. Mark Ahrens-Townsend Advisor NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.